Key result
Oxidative stress markers were significantly higher in patients with Cardiorenal Syndrome Type 1 compared to acute heart failure patients without AKI and controls (P < 0.05).
Observational (n=23)
p-value: p=< 0.05
Oxidative stress markers are significantly elevated in patients with Cardiorenal Syndrome Type 1 compared to those with acute heart failure alone, suggesting a potential therapeutic target.
Hypothesis-generating for oxidative stress targeting in CRS Type 1; prospective trials needed before clinical adoption.
Cardiorenal Syndrome Type 1 (Type 1) is a specific condition which is characterized by a rapid worsening of cardiac function leading to acute kidney injury (AKI). Even though its pathophysiology is complex and not still completely understood, oxidative stress seems to play a pivotal role. In this study, we examined the putative role of oxidative stress in the pathogenesis of CRS Type 1. Twenty-three patients with acute heart failure (AHF) were included in the study. Subsequently, 11 patients who developed AKI due to AHF were classified as CRS Type 1. Quantitative determinations for IL-6, myeloperoxidase (MPO), nitric oxide (NO), copper/zinc superoxide dismutase (Cu/ZnSOD), and endogenous peroxidase activity (EPA) were performed. CRS Type 1 patients displayed significant augmentation in circulating ROS and RNS, as well as expression of IL-6. Quantitative analysis of all oxidative stress markers showed significantly lower oxidative stress levels in controls and AHF compared to CRS Type 1 patients (P < 0.05). This pilot study demonstrates the significantly heightened presence of dual oxidative stress pathway induction in CRS Type 1 compared to AHF patients. Our findings indicate that oxidative stress is a potential therapeutic target, as it promotes inflammation by ROS/RNS-linked pathogenesis.
No takes yet. Share an insight, caveat, or question.
Virzì et al. (2015) conducted an observational in Cardiorenal Syndrome Type 1 (n=23). Oxidative stress vs. Acute heart failure patients without AKI and controls was evaluated on Levels of oxidative stress markers (IL-6, MPO, NO, Cu/ZnSOD, EPA) (p=< 0.05). Oxidative stress markers were significantly higher in patients with Cardiorenal Syndrome Type 1 compared to acute heart failure patients without AKI and controls (P < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: